305 related articles for article (PubMed ID: 8033141)
1. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Wheeler RH; Bucy RP; Liu T; Everson MP; Munn DH; Schlom J; LoBuglio AF
Cancer Res; 1995 Oct; 55(19):4339-46. PubMed ID: 7671245
[TBL] [Abstract][Full Text] [Related]
7. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
Jakubowski AA; Bajorin DF; Templeton MA; Chapman PB; Cody BV; Thaler H; Tao Y; Filippa DA; Williams L; Sherman ML; Garnick MB; Houghton AN
Clin Cancer Res; 1996 Feb; 2(2):295-302. PubMed ID: 9816172
[TBL] [Abstract][Full Text] [Related]
9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
J Natl Cancer Inst; 1994 Jan; 86(1):39-45. PubMed ID: 8271281
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
Rifkin RM; Hersh EM; Salmon SE
Behring Inst Mitt; 1988 Aug; (83):125-33. PubMed ID: 3071327
[TBL] [Abstract][Full Text] [Related]
12. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
[TBL] [Abstract][Full Text] [Related]
13. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
Berthaud P; Eugène-Jolchine I; Spielmann M; Le Chevalier T; Tursz T
Bull Cancer; 1993 May; 80(5):418-30. PubMed ID: 8173195
[TBL] [Abstract][Full Text] [Related]
14. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
Kaplan LD; Abrams DI; Sherwin SA; Kahn J; Volberding PA
Biotechnol Ther; 1989-1990; 1(3):229-36. PubMed ID: 2562651
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
